Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits immune cell activity while anti-VEGF augments intra-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nat Commun
Prif Awduron: Wallin, Jeffrey J., Bendell, Johanna C., Funke, Roel, Sznol, Mario, Korski, Konstanty, Jones, Suzanne, Hernandez, Genevive, Mier, James, He, Xian, Hodi, F. Stephen, Denker, Mitchell, Leveque, Vincent, Cañamero, Marta, Babitski, Galina, Koeppen, Hartmut, Ziai, James, Sharma, Neeraj, Gaire, Fabien, Chen, Daniel S., Waterkamp, Daniel, Hegde, Priti S., McDermott, David F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5013615/
https://ncbi.nlm.nih.gov/pubmed/27571927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12624
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg